We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+73.06%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$912M
AUM Growth
-$156M
Cap. Flow
-$257M
Cap. Flow %
-28.19%
Top 10 Hldgs %
35.78%
Holding
190
New
54
Increased
34
Reduced
35
Closed
53

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.96M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.6M
4
JBIO
Jade Biosciences
JBIO
+$8.03M
5
PYXS icon
Pyxis Oncology
PYXS
+$6.99M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$26.5M
2
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$21.4M
3
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$19.1M
4
NUVL
Nuvalent
NUVL
+$12.5M
5
IRON icon
Disc Medicine
IRON
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 39.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HOOK
126
DELISTED
HOOKIPA Pharma
HOOK
$378K 0.04%
53,078
– –
RLMD icon
127
Relmada Therapeutics
RLMD
$557M
$188K 0.02%
40,369
– –
CMMB
128
Chemomab Therapeutics
CMMB
$11.4M
$166K 0.02%
53,348
– –
STOK icon
129
Stoke Therapeutics
STOK
$1.8B
$92K 0.01%
6,816
-5,300
-44% -$32.1K
GPCR icon
130
CALL
Structure Therapeutics
GPCR
$3.41B
$85.7K 0.01%
+2,000
New +$84.3K
BCLI
131
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$51K 0.01%
6,016
– –
SYBX
132
DELISTED
Synlogic
SYBX
$36.6K ﹤0.01%
20,448
– –
EYPT icon
133
EyePoint Inc
EYPT
$1.03B
$21.6K ﹤0.01%
1,047
-367,083
-100% -$9.09M
FNCH
134
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$18.1K ﹤0.01%
6,892
– –
TYRA icon
135
Tyra Biosciences
TYRA
$1.9B
$8.22K ﹤0.01%
501
-47,669
-99% -$782K
ASLN
136
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$6.27K ﹤0.01%
4,428
– –
LBPH
137
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$5.1K ﹤0.01%
236
-979,226
-100% -$21.4M
ABBV icon
138
CALL
AbbVie
ABBV
$443B
– –
-132,500
Closed -$20.5M
ACRS icon
139
Aclaris Therapeutics
ACRS
$726M
– –
-19,482
Closed -$20.5K
APLS
140
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-150,000
Closed -$8.98M
ARGX icon
141
CALL
argenx
ARGX
$53.4B
– –
-78,100
Closed -$29.7M
ARGX icon
142
argenx
ARGX
$53.4B
– –
-70,000
Closed -$26.5M
ARGX icon
143
PUT
argenx
ARGX
$53.4B
– –
-78,100
Closed -$29.7M
AUTL
144
Autolus Therapeutics
AUTL
$397M
– –
-262,694
Closed -$1.69M
BDTX icon
145
Black Diamond Therapeutics
BDTX
$96.8M
– –
-555,572
Closed -$1.56M
CABA icon
146
Cabaletta Bio
CABA
$437M
– –
-216,620
Closed -$4.65M
CHRS icon
147
Coherus Oncology
CHRS
$217M
– –
-340,787
Closed -$1.13M
CLDX icon
148
PUT
Celldex Therapeutics
CLDX
$2.99B
– –
-200
Closed -$7.93K
CRSP icon
149
CALL
CRISPR Therapeutics
CRSP
$4.73B
– –
-3,900
Closed -$244K
CRSP icon
150
CRISPR Therapeutics
CRSP
$4.73B
– –
-70,546
Closed -$4.42M
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Ikarian Capital held 190 positions worth $912M, down 15% from $1.07B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Ikarian Capital withdrew a net $257M in Q1 2024, closing 53 positions and reducing 35 holdings. Its most notable exit was argenx, an estimated $26.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 32% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Alnylam Pharmaceuticals worth $7.7M.

  • Ikarian Capital's largest Q1 2024 buy was Alnylam Pharmaceuticals: 51,541 shares worth $7.7M.
  • Ikarian Capital added most to Corbus Pharmaceuticals in Q1 2024, an estimated $8.96M increase.
  • Ikarian Capital's biggest Q1 2024 reduction was Longboard Pharmaceuticals, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited argenx in Q1 2024, selling an estimated $26.5M.
  • Ikarian Capital's ten largest holdings make up 36% of its $912M portfolio in Q1 2024.
  • Ikarian Capital opened 54 new positions and closed 53 in Q1 2024.
  • Ikarian Capital's portfolio value fell 15% quarter-over-quarter to $912M.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.